Washington’s most-successful biotech company, MedImmune, will break ground today on a $250 million manufacturing plant in Frederick. The expansion, which will increase the Gaithersburg-based firm’s capacity to produce a number of therapeutics, is the next step in the evolution of the Washington region’s maturing biotech industry, officials said.
MedImmune’s expansion “is important. All of this is evolutionary,” said Aris Melissaratos, Maryland’s secretary of business and economic development. “For every drug in the pipeline, you want to get [to the manufacturing stage].”
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.